CASSAVA SCIENCES INC

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

FLNA$0.45+0.4%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Financial Statements Condensed Consolidated Balance Sheets – June 30, 2024 and December 31, 2023

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, In thousands, except share and par value data)

	June 30, 2024	December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents	$207,291	$121,136
Prepaid expenses and other current assets	14,831	8,497
Total current assets	222,122	129,633
Property and equipment, net	21,364	21,854
Intangible assets, net	82	176
Total assets	$243,568	$151,663
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses	$52,552	$10,573
Accrued development expense	1,596	3,037
Accrued compensation and benefits	218	200
Other current liabilities	228	385
Total current liabilities	54,594	14,195
Commitments and contingencies (Notes 9, 10 and 11)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding	—	—
Common stock, $0.001 par value; 120,000,000 shares authorized; 47,976,166 and 42,236,919 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	48	42
Additional paid-in capital	538,497	518,195
Accumulated deficit	(349,571)	(380,769)
Total stockholders' equity	188,974	137,468
Total liabilities and stockholders' equity	$243,568	$151,663

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.